Company profile
Cytochroma
Cytochroma Limited is a UK company with status active founded in 2017 based in Scotland.
Financial period: 1 Nov 2023 to 31 Oct 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
CH01 | Transaction MzQ0MDY3NDA0N2FkaXF6a2N4
Published 23 Oct 2024 12:04
CS01 | Transaction MzQ0MDY4MDEyMWFkaXF6a2N4
Published 23 Oct 2024 01:01
Company registered at Companies House
Cytochroma develops drug discovery technology.
Cytochroma's high throughput, automated screening platform delivers accurate toxicity information. From cell culture, to compound addition, all the way to data analysis and delivery. The Cytochroma assay is more sensitive than current cell health based assays and delivers significantly more information. It is fully customisable, at each step delivering all the data needed.
Dr Kate Cameron is fully funded by the BBSRC (Biotechnology and Biological Sciences Research Council) as one of the high prestigious Royal Society of Edinburgh Enterprise Fellowships. In the past few months she was awarded the highest amount possible, and special Higgs prize by Scottish EDGE in June. She came second in UoE annual competition Inspire Launch Grow awards and more recently, in September she placed in the top 2.5% of entrants, in the Converge Challenge. Funding and support from UoE, RSE + BBSRC has supported the lease of laboratory and office facilities at Roslin Innovation Centre, where she is currently based.
1 May 2022 to 30 Apr 2023
Unexpected cardiac adverse effects and lack of testing in distinct genetic backgrounds are the leading causes of clinical trial discontinuation, the withdrawal of drugs from the market and post-approval withdrawal of medicines. VISION This project aims to deliver physiologically relevant multicellular cardiac models from a diverse genetic background to mo...
1 Nov 2020 to 30 Apr 2021
Access to medicines and anti-viral vaccines would have significant societal, environmental, and economic impacts, both in the short and long term. The current COVID-19 pandemic has highlighted the inefficiency in how novel therapeutics are made and tested. New drug and vaccine development takes on average \>10 years, with costs in excess of 2 and 0.5 bill...
1 Jun 2020 to 30 Nov 2020
Access to medicines and anti-viral vaccines would have significant societal, environmental and economic impacts, both in the short and long term. The current Covid-19 pandemic has highlighted the inefficiency in how novel therapeutics are made and tested. New drug and vaccine development takes on average \>10 years, with costs in excess of 2 and 0.5 billi...
